Quarterly report · Q2
4574.TEDINET S100OZLM
Period2022-01-01 → 2022-06-30
Filed2022-08-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.9bn | 2022-01-01 → 2022-06-30 | Cons. | Net sales |
| Revenue | ¥11.3bn | 2021-01-01 → 2021-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥5.1bn | 2021-01-01 → 2021-06-30 | Cons. | Net sales |
| Operating income | −¥2.4bn | 2022-01-01 → 2022-06-30 | Cons. | Operating income |
| Operating income | −¥2.3bn | 2021-01-01 → 2021-06-30 | Cons. | Operating income |
| Ordinary income | −¥2.5bn | 2022-01-01 → 2022-06-30 | Cons. | Ordinary income |
| Ordinary income | −¥6.1bn | 2021-01-01 → 2021-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥2.7bn | 2021-01-01 → 2021-06-30 | Cons. | Ordinary income |
| Profit before tax | −¥2.8bn | 2022-01-01 → 2022-06-30 | Cons. | Income before income taxes |
| Profit before tax | −¥2.9bn | 2021-01-01 → 2021-06-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥2.8bn | 2022-01-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥9.6bn | 2021-01-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥2.4bn | 2021-01-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥2.8bn | 2022-01-01 → 2022-06-30 | Cons. | Profit loss |
| Net income | −¥2.4bn | 2021-01-01 → 2021-06-30 | Cons. | Profit loss |
| Total assets | ¥17.4bn | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥22.5bn | at 2021-12-31 | Cons. | Assets |
| Total assets | ¥27.2bn | at 2021-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.2bn | at 2022-06-30 | Cons. | Liabilities |
| Total liabilities | ¥9.7bn | at 2021-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥10.2bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥12.8bn | at 2021-12-31 | Cons. | Net assets |
| Net assets / equity | ¥20.0bn | at 2021-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.7bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥5.8bn | at 2021-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥4.4bn | at 2022-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.5bn | at 2021-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.7bn | at 2021-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.7bn | at 2020-12-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥631m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.6bn | 2021-01-01 → 2021-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥1.3bn | 2021-01-01 → 2021-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥96m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.6bn | 2021-01-01 → 2021-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.1bn | 2021-01-01 → 2021-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥501m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥4.0bn | 2021-01-01 → 2021-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥3.3bn | 2021-01-01 → 2021-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-64.17 | 2022-01-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-24.05 | 2022-04-01 → 2022-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-220.52 | 2021-01-01 → 2021-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-54.62 | 2021-01-01 → 2021-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-51.11 | 2021-04-01 → 2021-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 58.4% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.8% | at 2021-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.5% | at 2021-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2022-01-01 → 2022-06-30 | ¥4m |
| Otherother segments | revenue external | 2022-01-01 → 2022-06-30 | ¥4m |
| Otherother segments | segment profit | 2022-01-01 → 2022-06-30 | −¥11m |
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-06-30 | −¥645m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥365m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥365m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | segment profit | 2022-01-01 → 2022-06-30 | −¥1.6bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥1.5bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥1.5bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | segment profit | 2022-01-01 → 2022-06-30 | −¥117m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-01-01 → 2022-06-30 | ¥1.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-01-01 → 2022-06-30 | ¥1.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-01-01 → 2022-06-30 | −¥1.8bn |
| Otherother segments | revenue | 2021-01-01 → 2021-06-30 | ¥3m |
| Otherother segments | revenue external | 2021-01-01 → 2021-06-30 | ¥3m |
| Otherother segments | segment profit | 2021-01-01 → 2021-06-30 | −¥12m |
| Reconciling Itemsreconciling | segment profit | 2021-01-01 → 2021-06-30 | −¥723m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue | 2021-01-01 → 2021-06-30 | ¥3.1bn |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue external | 2021-01-01 → 2021-06-30 | ¥3.1bn |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | segment profit | 2021-01-01 → 2021-06-30 | −¥2.1bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue | 2021-01-01 → 2021-06-30 | ¥2.0bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue external | 2021-01-01 → 2021-06-30 | ¥2.0bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | segment profit | 2021-01-01 → 2021-06-30 | ¥594m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-01-01 → 2021-06-30 | ¥5.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-01-01 → 2021-06-30 | ¥5.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-01-01 → 2021-06-30 | −¥1.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 517
| Item | Context | Value | Unit |
|---|---|---|---|
| Interest and dividends income received ope cf inv cf | CurrentYTDDuration | 4000000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1YTDDuration | -2000000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYTDDuration | -6000000 | JPY |
| Income taxes paid ope cf | Prior1YTDDuration | -1018000000 | JPY |
| Income taxes paid ope cf | CurrentYTDDuration | -4000000 | JPY |
| Net cash provided by used in operating activities | Prior1YTDDuration | -1259000000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration | -631000000 | JPY |
| Payments into time deposits inv cf | Prior1YTDDuration | -7000000 | JPY |
| Payments into time deposits inv cf | CurrentYTDDuration | -17000000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | Prior1YTDDuration | 10000000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | CurrentYTDDuration | 3000000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1YTDDuration | -1132000000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYTDDuration | -60000000 | JPY |
| Purchase of intangible assets inv cf | Prior1YTDDuration | -94000000 | JPY |
| Purchase of intangible assets inv cf | CurrentYTDDuration | -12000000 | JPY |
| Proceeds from sales and redemption of investment securities inv cf | Prior1YTDDuration | 80000000 | JPY |
| Proceeds from sales and redemption of investment securities inv cf | CurrentYTDDuration | － | JPY |
| Purchase of investments in subsidiaries inv cf | Prior1YTDDuration | － | JPY |
| Purchase of investments in subsidiaries inv cf | CurrentYTDDuration | -9000000 | JPY |
| Other net inv cf | Prior1YTDDuration | -6000000 | JPY |
| Other net inv cf | CurrentYTDDuration | － | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -1149000000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -96000000 | JPY |
| Proceeds from long term loans payable fin cf | Prior1YTDDuration | 4000000000 | JPY |
| Proceeds from long term loans payable fin cf | CurrentYTDDuration | － | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | － | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -473000000 | JPY |
| Repayments of lease obligations fin cf | Prior1YTDDuration | -16000000 | JPY |
| Repayments of lease obligations fin cf | CurrentYTDDuration | -19000000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -780000000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -0 | JPY |
| Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cf | Prior1YTDDuration | 101000000 | JPY |
| Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cf | CurrentYTDDuration | － | JPY |
| Other net fin cf | Prior1YTDDuration | － | JPY |
| Other net fin cf | CurrentYTDDuration | -8000000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | 3305000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -501000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 58000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | 87000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 954000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -1141000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 4698000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 5521000000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 5652000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 4379000000 | JPY |
| Write downs of inventories | Prior1YTDDuration | 1721000000 | JPY |
| Write downs of inventories | CurrentYTDDuration | 592000000 | JPY |
| Advertising expenses sga | Prior1YTDDuration | 962000000 | JPY |
| Advertising expenses sga | CurrentYTDDuration | 219000000 | JPY |
| Payroll and allowances sga | Prior1YTDDuration | 566000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |